Senexin B is primarily utilized in the field of cancer research due to its ability to inhibit cyclin-dependent kinases (CDKs), which play a critical role in regulating cell cycle progression. By targeting these kinases, it helps in halting the proliferation of cancer cells, making it a potential candidate for the development of anticancer therapies. Additionally, its application extends to studying cellular mechanisms and pathways involved in tumor growth, providing insights for novel therapeutic strategies. Researchers also explore its potential in combination with other treatments to enhance efficacy and overcome drug resistance in various cancer types.